login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
IMMUNIC INC (IMUX) Stock News
USA
-
Nasdaq
- NASDAQ:IMUX -
US4525EP1011
-
Common Stock
0.6864
USD
0 (-0.16%)
Last: 11/21/2025, 8:00:02 PM
0.6857
USD
0 (-0.1%)
After Hours:
11/21/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IMUX Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Benzinga
- Mentions:
IBIO
ENGN
IMCC
VREX
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
10 days ago - By: Immunic, Inc.
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
25 days ago - By: Immunic, Inc.
Immunic to Participate in Industry and Investor Conferences in November
2 months ago - By: Immunic, Inc.
Immunic to Participate in Scientific and Investor Conferences in October
2 months ago - By: Benzinga
- Mentions:
EA
MLTX
ANRO
This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
4 months ago - By: The Motley Fool
Immunic (IMUX) Q2 Loss Widens 25%
5 months ago - By: Stocktwits
Immunic to Participate in Scientific and Industry Conferences in May
5 months ago - By: Stocktwits
Immunic, Inc. Announces Proposed Public Offering
2 months ago - By: Immunic, Inc.
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
2 months ago - By: Immunic, Inc.
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
3 months ago - By: Immunic, Inc.
Immunic to Participate in Investor and Scientific Conferences in September
4 months ago - By: Immunic, Inc.
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
5 months ago - By: Stocktwits
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
5 months ago - By: Stocktwits
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
5 months ago - By: Stocktwits
- Mentions:
UBS
Immunic to Participate in Investor, Scientific and Industry Conferences in June
5 months ago - By: Stocktwits
- Mentions:
IMU
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
6 months ago - By: Immunic, Inc.
Immunic, Inc. Announces Proposed Public Offering
5 months ago - By: Stocktwits
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
5 months ago - By: Stocktwits
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
5 months ago - By: Immunic, Inc.
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
6 months ago - By: Immunic, Inc.
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
6 months ago - By: Immunic, Inc.
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
6 months ago - By: Immunic, Inc.
Immunic to Participate in Investor, Scientific and Industry Conferences in June
6 months ago - By: Immunic, Inc.
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
7 months ago - By: Immunic, Inc.
Immunic to Participate in Scientific and Industry Conferences in May
7 months ago - By: Immunic, Inc.
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
8 months ago - By: Immunic, Inc.
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
8 months ago - By: Stocktwits
- Mentions:
VTI
VXF
Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode
8 months ago - By: Immunic, Inc.
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
8 months ago - By: Immunic, Inc.
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
9 months ago - By: Immunic, Inc.
Immunic to Participate in Scientific and Investor Conferences in March
Please enable JavaScript to continue using this application.